R2AR34 Stock Overview
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$23.38 |
52 Week High | US$23.38 |
52 Week Low | US$15.78 |
Beta | 0.66 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -36.79% |
Recent News & Updates
Recent updates
Shareholder Returns
R2AR34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | 0% | 1.2% | 0.4% |
1Y | n/a | -4.9% | 13.9% |
Return vs Industry: Insufficient data to determine how R2AR34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how R2AR34 performed against the BR Market.
Price Volatility
R2AR34 volatility | |
---|---|
R2AR34 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 4.7% |
10% most volatile stocks in BR Market | 8.8% |
10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: R2AR34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine R2AR34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
R2AR34 fundamental statistics | |
---|---|
Market cap | R$19.16b |
Earnings (TTM) | -R$3.13b |
Revenue (TTM) | R$2.24b |
8.4x
P/S Ratio-6.0x
P/E RatioIs R2AR34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
R2AR34 income statement (TTM) | |
---|---|
Revenue | US$434.25m |
Cost of Revenue | US$119.74m |
Gross Profit | US$314.51m |
Other Expenses | US$921.15m |
Earnings | -US$606.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -7.37 |
Gross Margin | 72.43% |
Net Profit Margin | -139.70% |
Debt/Equity Ratio | 323.7% |
How did R2AR34 perform over the long term?
See historical performance and comparison